Literature DB >> 29128965

Abemaciclib: First Global Approval.

Esther S Kim1.   

Abstract

Abemaciclib (Verzenio™) is an orally administered inhibitor of cyclin-dependent kinases 4 and 6 that is being developed by Eli Lilly and Company. Abemaciclib has been approved in the USA for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, in combination with fulvestrant in women with disease progression following endocrine therapy, and as monotherapy in adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. In addition, abemaciclib is in various stages of development internationally for a variety of cancers. This article summarizes the milestones in the development of abemaciclib leading to its first approval for the treatment of patients with HR-positive, HER2-negative advanced or metastatic breast cancer.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29128965     DOI： 10.1007/s40265-017-0840-z

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  10 in total

Review 1.  Proliferation marker Ki-67 in early breast cancer.

Authors:  Ander Urruticoechea; Ian E Smith; Mitch Dowsett
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

2.  Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.

Authors:  Jonathan W Goldman; Peipei Shi; Martin Reck; Luis Paz-Ares; Andrew Koustenis; Karla C Hurt
Journal:  Clin Lung Cancer       Date:  2015-08-18       Impact factor: 4.785

3.  MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

Authors:  Maura N Dickler; Sara M Tolaney; Hope S Rugo; Javier Cortés; Véronique Diéras; Debra Patt; Hans Wildiers; Clifford A Hudis; Joyce O'Shaughnessy; Esther Zamora; Denise A Yardley; Martin Frenzel; Andrew Koustenis; José Baselga
Journal:  Clin Cancer Res       Date:  2017-05-22       Impact factor: 12.531

4.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

Authors:  George W Sledge; Masakazu Toi; Patrick Neven; Joohyuk Sohn; Kenichi Inoue; Xavier Pivot; Olga Burdaeva; Meena Okera; Norikazu Masuda; Peter A Kaufman; Han Koh; Eva-Maria Grischke; Martin Frenzel; Yong Lin; Susana Barriga; Ian C Smith; Nawel Bourayou; Antonio Llombart-Cussac
Journal:  J Clin Oncol       Date:  2017-06-03       Impact factor: 44.544

Review 5.  Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.

Authors:  Dorota Kwapisz
Journal:  Breast Cancer Res Treat       Date:  2017-07-24       Impact factor: 4.872

6.  MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

Authors:  Matthew P Goetz; Masakazu Toi; Mario Campone; Joohyuk Sohn; Shani Paluch-Shimon; Jens Huober; In Hae Park; Olivier Trédan; Shin-Cheh Chen; Luis Manso; Orit C Freedman; Georgina Garnica Jaliffe; Tammy Forrester; Martin Frenzel; Susana Barriga; Ian C Smith; Nawel Bourayou; Angelo Di Leo
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

7.  Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.

Authors:  Yutaka Fujiwara; Kenji Tamura; Shunsuke Kondo; Yuko Tanabe; Satoru Iwasa; Akihiko Shimomura; Shigehisa Kitano; Ken Ogasawara; P Kellie Turner; Joji Mori; Hiroya Asou; Edward Michael Chan; Noboru Yamamoto
Journal:  Cancer Chemother Pharmacol       Date:  2016-06-16       Impact factor: 3.333

8.  Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

Authors:  Amita Patnaik; Lee S Rosen; Sara M Tolaney; Anthony W Tolcher; Jonathan W Goldman; Leena Gandhi; Kyriakos P Papadopoulos; Muralidhar Beeram; Drew W Rasco; John F Hilton; Aejaz Nasir; Richard P Beckmann; Andrew E Schade; Angie D Fulford; Tuan S Nguyen; Ricardo Martinez; Palaniappan Kulanthaivel; Lily Q Li; Martin Frenzel; Damien M Cronier; Edward M Chan; Keith T Flaherty; Patrick Y Wen; Geoffrey I Shapiro
Journal:  Cancer Discov       Date:  2016-05-23       Impact factor: 39.397

Review 9.  Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.

Authors:  Richard S Finn; Alexey Aleshin; Dennis J Slamon
Journal:  Breast Cancer Res       Date:  2016-02-09       Impact factor: 6.466

Review 10.  Recent advances of highly selective CDK4/6 inhibitors in breast cancer.

Authors:  Hanxiao Xu; Shengnan Yu; Qian Liu; Xun Yuan; Sridhar Mani; Richard G Pestell; Kongming Wu
Journal:  J Hematol Oncol       Date:  2017-04-24       Impact factor: 17.388
  10 in total
  17 in total

Review 1.  CDK9 inhibitors in cancer research.

Authors:  Zhi Huang; Tianqi Wang; Cheng Wang; Yan Fan
Journal:  RSC Med Chem       Date:  2022-04-20

2.  Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice.

Authors:  Jingjing Duan; Zhuo Wang; Ran Duan; Chenxinhui Yang; Ruolin Zhao; Qi Feng; Yuanyuan Qin; Jingwei Jiang; Shouyong Gu; Kaiyan Lv; Libo Zhang; Bixia He; Lutz Birnbaumer; Song Yang; Zhen Chen; Yong Yang
Journal:  Hepatology       Date:  2021-11-27       Impact factor: 17.298

Review 3.  Molecular perspective on targeted therapy in breast cancer: a review of current status.

Authors:  Busra Demir Cetinkaya; Cigir Biray Avci
Journal:  Med Oncol       Date:  2022-07-14       Impact factor: 3.738

Review 4.  The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer.

Authors:  Hirokazu Kimura; Alison P Klein; Ralph H Hruban; Nicholas J Roberts
Journal:  Pancreas       Date:  2021-09-01       Impact factor: 3.243

Review 5.  Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers.

Authors:  Z Ping Lin; Yong-Lian Zhu; Elena S Ratner
Journal:  Front Oncol       Date:  2018-08-08       Impact factor: 6.244

Review 6.  The application and prospect of CDK4/6 inhibitors in malignant solid tumors.

Authors:  Qi Du; Xiang Guo; Miao Wang; Yongfu Li; Xiaoyi Sun; Qin Li
Journal:  J Hematol Oncol       Date:  2020-05-01       Impact factor: 17.388

7.  Discovery of 12O-A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor.

Authors:  Yan Fan; Zhi Huang; Xiaoshuang Wang; Yakun Ma; Yongtao Li; Shengyong Yang; Yi Shi
Journal:  Molecules       Date:  2020-11-09       Impact factor: 4.411

8.  Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.

Authors:  Xiuzhi Zhu; Li Chen; Binhao Huang; Xiaoguang Li; Liu Yang; Xin Hu; Yizhou Jiang; Zhimin Shao; Zhonghua Wang
Journal:  J Exp Clin Cancer Res       Date:  2021-04-08

Review 9.  Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets.

Authors:  Alexandros Karagiannakos; Maria Adamaki; Antonis Tsintarakis; Borek Vojtesek; Robin Fåhraeus; Vassilis Zoumpourlis; Konstantinos Karakostis
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

10.  The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis.

Authors:  Zhanzhan Feng; Yong Xia; Tiantao Gao; Fuyan Xu; Qian Lei; Cuiting Peng; Yufei Yang; Qiang Xue; Xi Hu; Qianqian Wang; Ranran Wang; Zhiqiang Ran; Zhilin Zeng; Nan Yang; Zixin Xie; Luoting Yu
Journal:  Cell Death Dis       Date:  2018-09-26       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.